Döscher J, Busch C-J, Schuler P J, Laban S
Klinik für Hals-Nasen-Ohrenheilkunde und Kopf-Hals-Chirurgie, Universitätsklinik Ulm, Frauensteige 12, 89070, Ulm, Deutschland.
Klinik für Hals-Nasen-Ohrenheilkunde und Kopf-Hals-Chirurgie und Onkologie, Kopf-Hals-Tumorzentrum des UCCH, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
HNO. 2016 Oct;64(10):700-7. doi: 10.1007/s00106-016-0241-8.
Immunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.
On occasion of the annual meeting of the American Society of Clinical Oncology (ASCO), we aimed to invesitage the future of immunotherapies.
We collected the most promising upcoming studies alongside current research in the field of biomarkers with a view to interesting new immunotherapeutic strategies.
The search for appropriate biomarkers in particular seems to be a central research objective in the short term. There is a broad range of new agents that will be tested in clinical trials as well as the combination of immunotherapy with chemo- and chemoradiotherapy or other immune-modulating drugs.
The real challenge will be to find the most fitting therapy for each patient out of a large panel of available regimens. Therefore, it is most important to find a set of reliable biomarkers that together could predict treatment response.
免疫疗法仍是一个热门话题，新的临床试验层出不穷。迄今为止的研究结果对于头颈部鳞状细胞癌（HNSCC）的二线姑息治疗很有前景。下一步是在一线治疗以及辅助、新辅助和主要是非手术治疗的根治性治疗的随机试验中测试这些策略。到目前为止，已确立的生物标志物尚未被证明足够可靠，无法精确预测缓解率。
在美国临床肿瘤学会（ASCO）年会之际，我们旨在探讨免疫疗法的未来。
我们收集了最有前景的即将开展的研究以及该领域目前的生物标志物研究，以关注有趣的新免疫治疗策略。
短期内，寻找合适的生物标志物似乎是核心研究目标。有大量新药物将在临床试验中进行测试，以及免疫疗法与化疗、放化疗或其他免疫调节药物的联合应用。
真正的挑战将是从大量可用方案中为每位患者找到最合适的治疗方法。因此，找到一组能够共同预测治疗反应的可靠生物标志物至关重要。
